Skip to content

BJCP article: Analysis examines safety of antidepressant use during pregnancy

Use of fluoxetine – the most commonly prescribed antidepressant – during pregnancy is linked with a slightly increased risk of malformations in infants, according to a recent analysis of published studies.

In the analysis of 16 studies, infants exposed to fluoxetine during the first trimester had an 18% increased relative risk of major malformations and a 36% increased relative risk of cardiovascular malformations. There were no significant observations of other system-specific malformations in the nervous system, eye, urogenital system, digestive system, respiratory system, or musculoskeletal system.

The findings are published in the British Journal of Clinical Pharmacology.

Similar research was published at an earlier time in the British Journal of Clinical Pharmacology

Latest news & activity

Governance

Apply/nominate by 21 October 2026

Scholarship/studentship

The British Pharmacological Society is delighted to launch its PhD Funding Programme for awards in 2027.

The programme includes both the AJ Clark…

Prizes and awards

The Federation of European Pharmacological Societies (EPHAR) has opened applications for its Young Investigators Award 2026. Two awards of €1,000 each…